|1.||Meyers, N L: 4 articles (12/2008 - 06/2006)|
|2.||Hickling, R I: 3 articles (12/2008 - 11/2007)|
|3.||Abdollahi, Mohammad: 2 articles (05/2014 - 02/2014)|
|4.||Mozaffari, Shilan: 2 articles (05/2014 - 02/2014)|
|5.||Nikfar, Shekoufeh: 2 articles (05/2014 - 02/2014)|
|6.||Burton, Duane: 2 articles (02/2013 - 10/2004)|
|7.||Camilleri, Michael: 2 articles (02/2013 - 10/2004)|
|8.||Zinsmeister, Alan R: 2 articles (02/2013 - 10/2004)|
|9.||Lewis, James H: 1 article (07/2011)|
|10.||Adam, Birgit: 1 article (07/2010)|
|1.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
01/01/2008 - "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome."
11/01/2007 - "The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome."
02/24/2014 - "Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients."
12/01/2008 - "This was an exploratory study of renzapride in 168 male and female patients with non-D, non-C irritable bowel syndrome (IBS). "
12/01/2008 - "Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial."
01/01/2008 - "Clinical studies have confirmed the therapeutic efficacy, tolerability and safety of renzapride in patients with constipation-predominant IBS. "
02/24/2014 - "Renzapride is a full agonist for 5HT4 receptor and an antagonist to 5HT2b and 5HT3 receptors which is thought a promising therapeutic agent for constipation predominant IBS (C-IBS) patients due to its accelerating effect on the GI tract. "
06/01/2006 - "Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome."
05/01/2010 - "Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study."
06/01/2006 - "This study has established proof of concept and supports further investigation of renzapride in patients with constipation-predominant irritable bowel syndrome."
|3.||Abdominal Pain (Pain, Abdominal)
05/01/2008 - "Although there were no statistically significant differences between renzapride and placebo for relief from abdominal pain/discomfort, responder rates in the renzapride treatment groups increased dose dependently, with the 4 mg/day group being consistently numerically greater than placebo. "
06/01/2006 - "Renzapride also reduced abdominal pain, increased the number of pain-free days and improved stool consistency. "
05/01/2008 - "To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort in patients with constipation-predominant irritable bowel syndrome. "
04/01/1991 - "Renzapride may be useful in the treatment of diabetic gastroparesis."
09/01/1991 - "An alpha 2-adrenergic agonist can be used to model gastroparesis in dogs by inhibiting antroduodenal motility and can also be used to examine the actions of motor stimulants, such as renzapride, which promote gastric emptying."
09/01/1991 - "Alpha 2-adrenergic model of gastroparesis: validation with renzapride, a stimulator of motility."
04/01/1991 - "The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis."
10/01/2005 - "5-Hydroxytryptamine4 receptors are targets for drugs (tegaserod, renzapride) that treat symptoms in constipated irritable bowel syndrome patients and in gastroparesis. "
02/24/2014 - "Renzapride is not superior to placebo in relieving IBS symptoms and causes significant incidences of diarrhea and drop-outs due to adverse effects in treated patients vs. placebo. "
02/24/2014 - "The analysis of tolerability demonstrated that amongst different reported adverse effects, renzapride caused diarrhea more than placebo (RR = 1.61 with a 95% CI = 1.16-2.24, p = 0.004). "
05/01/2014 - "Diarrhea was significantly higher versus placebo following use of linaclotide and renzapride, similar to that of constipation with ramosetron. "
02/01/2013 - "We evaluated data from placebo arm of 9 phase IIA, parallel-group, clinical trials of PD effects of linaclotide, dexloxiglumide, renzapride, elobixibat, ROSE 010, and chenodeoxycholate in lower FGID with constipation, and pexacerafont, VSL#3, and colesevelam in lower FGID with diarrhea. "
|3.||Serotonin (5 Hydroxytryptamine)
|8.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|10.||Chenodeoxycholic Acid (Chenix)
|1.||Nebulizers and Vaporizers (Inhaler)
|2.||Drug Therapy (Chemotherapy)